Review
Pharmacology & Pharmacy
Kajetan Kielbowski, Justyna Zychowska, Rafal Becht
Summary: This review summarizes the efficacy and safety profile of ALK inhibitors, describes off-target anticancer effects, and discusses resistance mechanisms in the context of personalized oncology.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Oncology
Chanjuan Shi, Michael A. Morse
Summary: This article summarizes the treatment methods for advanced neuroendocrine tumors in the intestinal tract and pancreas, as well as the limitations in therapeutic resistance. Although the mechanisms of resistance are poorly understood, early studies suggest that combination therapy or the use of novel targeted drugs may be promising.
Article
Endocrinology & Metabolism
Matti L. Gild, Martyn Bullock, Venessa Tsang, Roderick J. Clifton-Bligh, Bruce G. Robinson, Lori J. Wirth
Summary: This study identified actionable targets in thyroid cancer, including mutations in BRAF(V600E), N/H/K RAS, and oncogenic kinase fusions involving NTRK, RET, ALK, and ROS1. However, acquired resistance may develop, necessitating the exploration of new therapeutic strategies.
Review
Oncology
Yue Pan, Chao Deng, Zhenhua Qiu, Chenghui Cao, Fang Wu
Summary: This review discusses the resistance mechanisms of ALK TKIs in advanced NSCLC, providing a theoretical basis and research ideas for solving the problem of ALK drug resistance.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
J. R. Brown, B. Eichhorst, P. Hillmen, W. Jurczak, M. Kazmierczak, N. Lamanna, S. M. O'Brien, C. S. Tam, L. Qiu, K. Zhou, M. Simkovic, J. Mayer, A. Gillespie-Twardy, A. Ferrajoli, P. S. Ganly, R. Weinkove, S. Grosicki, A. Mital, T. Robak, A. Osterborg, H. A. Yimer, T. Salmi, M. -D. -Y. Wang, L. Fu, J. Li, K. Wu, A. Cohen, M. Shadman
Summary: In a multinational phase 3 trial, zanubrutinib was found to be superior to ibrutinib in treating relapsed or refractory CLL or SLL, with better efficacy and fewer side effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Summary: The study compared the efficacy and safety of zanubrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The results showed that zanubrutinib had better outcomes in terms of efficacy, atrial fibrillation rate, and cardiac safety compared to ibrutinib.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Hematology
John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach
Summary: ELEVATE-RR trial showed that acalabrutinib has noninferior progression-free survival and lower incidence of key adverse events compared to ibrutinib in previously treated chronic lymphocytic leukemia patients. Post hoc analysis further characterized the adverse events of acalabrutinib and ibrutinib. It was found that acalabrutinib had higher incidence rates of headache and cough, while ibrutinib had higher rates of diarrhea, joint pain, urinary tract infection, back pain, muscle spasms, and dyspepsia. Ibrutinib also had higher rates of atrial fibrillation/flutter, hypertension, and bleeding. The discontinuation rate due to adverse events was lower with acalabrutinib. The overall event-based analyses and adverse event burden scores demonstrated that ibrutinib had a higher burden of adverse events compared to acalabrutinib, particularly in atrial fibrillation, hypertension, and bleeding.
Review
Oncology
Emmy D. G. Fleuren, Myrella Vlenterie, Winette T. A. van der Graaf
Summary: Osteosarcoma (OS) and Ewing sarcoma (ES) are two common types of primary bone cancer that mainly affect young people. Despite aggressive treatment, survival rates have not significantly improved in the past four decades. Clinical efficacy has been observed with some mono-Receptor Tyrosine Kinase (RTK) inhibitors, but only in small subsets of patients. Newer generation multi-RTK inhibitors have shown efficacy in larger groups of OS or ES patients. However, registration for these indications has not been obtained, making it difficult to implement these drugs in routine patient care.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Vignesh Sivaganesh, Varsha Sivaganesh, Christina Scanlon, Alexander Iskander, Salma Maher, Thu Le, Bela Peethambaran
Summary: Protein tyrosine phosphatases (PTPs) have emerged as a new target in cancer therapy, with both tumor-suppressive and oncogenic properties. This review focuses on key PTPs investigated in various cancers and explores the different mechanisms underlying pro-cancerous and anti-cancerous effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cardiac & Cardiovascular Systems
Monika E. Grabowska, Bryan Chun, Raquel Moya, Jeffrey J. Saucerman
Summary: This study investigates the molecular mechanisms of cardiotoxicity induced by tyrosine kinase inhibitors, using a computational model of cardiomyocyte apoptosis. It predicts the levels of apoptosis induced by different TKIs and identifies positive and negative regulators of apoptosis. Combinatorial screening reveals potential strategies to reduce TKI-induced apoptosis in cardiomyocytes.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
(2021)
Article
Medicine, General & Internal
Lin-Quan Tang, Xiao-Yun Li, Zhi-Ming Li, Zhi-Gang Liu, Miao-Zhen Lin, Huan Zhou, Qi-Wen Yu, Jian Zhou, Chong Zhao, Ze-Bin Chen, Xi-Cheng Wang, Jia-Yu Peng, Qiu-Yan Chen, Wen-Feng Fang, Yun-Peng Yang, Bei Zhang, Liang-Ping Xia, Pi-Li Hu, Wei-Han Hu, Yi-Jie Li, Hai-Qiang Mai, Xiu-Yu Cai
Summary: Apatinib combined with capecitabine shows promising efficacy as a second-line treatment option in pretreated platinum-refractory recurrent or metastatic nasopharyngeal carcinoma patients.
Article
Multidisciplinary Sciences
Nir Drayman, Jennifer K. DeMarco, Krysten A. Jones, Saara-Anne Azizi, Heather M. Froggatt, Kemin Tan, Natalia Ivanovna Maltseva, Siquan Chen, Vlad Nicolaescu, Steve Dvorkin, Kevin Furlong, Rahul S. Kathayat, Mason R. Firpo, Vincent Mastrodomenico, Emily A. Bruce, Madaline M. Schmidt, Robert Jedrzejczak, Miguel A. Munoz-Alia, Brooke Schuster, Vishnu Nair, Kyu-yeon Han, Amornrat O'Brien, Anastasia Tomatsidou, Bjoern Meyer, Marco Vignuzzi, Dominique Missiakas, Jason W. Botten, Christopher B. Brooke, Hyun Lee, Susan C. Baker, Bryan C. Mounce, Nicholas S. Heaton, William E. Severson, Kenneth E. Palmer, Bryan C. Dickinson, Andrzej Joachimiak, Glenn Randall, Savas Tay
Summary: This study identified a drug called masitinib that can inhibit the replication of both SARS-CoV-2 and OC43 virus, and acts by competitively inhibiting 3CLpro. The drug showed strong antiviral effects in in vivo experiments on mice infected with SARS-CoV-2, and was effective against multiple variants in vitro.
Review
Pharmacology & Pharmacy
Qi Zhao, Zhanxuan E. Wu, Bin Li, Fei Li
Summary: Small molecule tyrosine kinase inhibitors (TKIs) are widely used as anticancer drugs, but their toxicities to multiple organs limit their clinical applications. Metabolomics can identify toxic metabolites and metabolic derangement associated with TKI exposure, and has revealed the affected metabolic pathways. Modulation of xenobiotic receptor signaling, inhibition of xenobiotic metabolism, and supplementation of endogenous metabolites are potential strategies to prevent TKI-induced toxicity.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Pharmacology & Pharmacy
Sareshma Sudhesh Dev, Syafiq Asnawi Zainal Abidin, Reyhaneh Farghadani, Iekhsan Othman, Rakesh Naidu
Summary: Receptor tyrosine kinases (RTKs) are crucial cell-surface proteins that regulate essential cellular processes, with alterations in them playing a key role in cancer progression. Curcumin, as an attractive anti-cancer agent, exhibits potent effects by inhibiting RTKs and downstream signaling pathways.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemical Research Methods
Gregory J. Tawa, John Braisted, David Gerhold, Gurmit Grewal, Christina Mazcko, Matthew Breen, Gurusingham Sittampalam, Amy K. LeBlanc
Summary: Understanding the shared cancer biology between canines and humans through analyzing canine transcriptomics data can aid in biomarker and drug development in humans. Unique co-expression modules were identified in different types of canine cancer, and the classification models derived from canine data successfully classified human tumors, suggesting potential transferability of findings from canines to humans in terms of tumor biology and therapeutic targets.
PLOS COMPUTATIONAL BIOLOGY
(2021)
Review
Oncology
Bronwen J. Mayo, Andrea M. Stringer, Joanne M. Bowen, Emma H. Bateman, Dorothy M. Keefe
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2017)
Article
Oncology
Janet K. Coller, Joanne M. Bowen, Imogen A. Ball, Hannah R. Wardill, Ysabella Z. A. van Sebille, Romany L. Stansborough, Zenab Lightwala, Anthony Wignall, Joseph Shirren, Kate Secombe, Rachel J. Gibson
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2017)
Review
Genetics & Heredity
J. M. Campbell, M. D. Stephenson, E. Bateman, M. D. J. Peters, D. M. Keefe, J. M. Bowen
PHARMACOGENOMICS JOURNAL
(2017)
Article
Oncology
Noor Al-Dasooqi, Joanne Bowen, Colin Bennett, John Finnie, Dorothy Keefe, Rachel Gibson
SUPPORTIVE CARE IN CANCER
(2017)
Article
Oncology
Ysabella Z. A. Van Sebille, Rachel J. Gibson, Hannah R. Wardill, Kate R. Secombe, Imogen A. Ball, Dorothy M. K. Keefe, John W. Finnie, Joanne M. Bowen
INTERNATIONAL JOURNAL OF CANCER
(2017)
Article
Oncology
Ysabella Z. A. Van Sebille, Rachel J. Gibson, Hannah R. Wardill, Imogen A. Ball, Dorothy M. K. Keefe, Joanne M. Bowen
INTERNATIONAL JOURNAL OF CANCER
(2018)
Article
Oncology
Romany L. Stansborough, Emma H. Bateman, Noor Al-Dasooqi, Joanne M. Bowen, Dorothy M. K. Keefe, Ann S. J. Yeoh, Richard M. Logan, Eric E. K. Yeoh, Andrea M. Stringer, Rachel J. Gibson
SUPPORTIVE CARE IN CANCER
(2017)
Article
Oncology
K. Fakiha, J. K. Coller, R. M. Logan, R. J. Gibson, J. M. Bowen
SUPPORTIVE CARE IN CANCER
(2019)
Article
Medicine, Research & Experimental
Ysabella Z. A. Van Sebille, Rachel J. Gibson, Hannah R. Wardill, Thomas J. Carney, Joanne M. Bowen
EXPERIMENTAL BIOLOGY AND MEDICINE
(2019)
Article
Oncology
J. Bowen, N. Al-Dasooqi, P. Bossi, H. Wardill, Y. van Sebille, A. Al-Azri, E. Bateman, M. E. Correa, J. Raber-Durlacher, A. Kandwal, B. Mayo, R. G. Nair, A. Stringer, K. ten Bohmer, D. Thorpe, R. V. Lalla, S. Sonis, K. Cheng, S. Elad
SUPPORTIVE CARE IN CANCER
(2019)
Review
Oncology
Joanne M. Bowen, Rachel J. Gibson, Janet K. Coller, Nicole Blijlevens, Paolo Bossi, Noor Al-Dasooqi, Emma H. Bateman, Karen Chiang, Charlotte de Mooij, Bronwen Mayo, Andrea M. Stringer, Wim Tissing, Hannah R. Wardill, Ysabella Z. A. van Sebille, Vinisha Ranna, Anusha Vaddi, Dorothy M. K. Keefe, Rajesh V. Lalla, Karis Kin Fong Cheng, Sharon Elad
SUPPORTIVE CARE IN CANCER
(2019)
Article
Oncology
Sharon Elad, Karis Kin Fong Cheng, Rajesh V. Lalla, Noam Yarom, Catherine Hong, Richard M. Logan, Joanne Bowen, Rachel Gibson, Deborah P. Saunders, Yehuda Zadik, Anura Ariyawardana, Maria Elvira Correa, Vinisha Ranna, Paolo Bossi
Review
Cell Biology
Elise E. Bruning, Janet K. Coller, Hannah R. Wardill, Joanne M. Bowen
Summary: TLR4 is a highly conserved protein involved in innate immunity with distinct roles in epithelial and immune cells throughout the gastrointestinal tract. While epithelial cell expression of TLR4 contributes to maintaining homeostasis, promoting immunoglobulin A production, and regulating permeability, immune cell expression is centered on maturation of dendritic cells and priming the adaptive immune system. However, further research is needed to fully understand the impact of site-specific TLR4 expression on inflammation and disease progression.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Editorial Material
Oncology
Joanne Bowen, Hannah Wardill
SUPPORTIVE CARE IN CANCER
(2022)
Review
Biotechnology & Applied Microbiology
Raja Nur Firzanah Syaza Raja Sharin, Jesmine Khan, Mohamad Johari Ibahim, Mudiana Muhamad, Joanne Bowen, Wan Nor I'zzahWan Mohamad Zain
Summary: Lapatinib, a tyrosine kinase inhibitor, is effective in treating ErbB2-positive breast cancer; however, it often causes gastrointestinal toxicity, specifically diarrhea. This review article explores the mechanisms of lapatinib-induced diarrhea, focusing on the involvement of ErbB1 and its role in inflammation and intestinal permeability.
BIOMED RESEARCH INTERNATIONAL
(2022)